Sensus Healthcare - SRTS Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sensus Healthcare in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SRTS shares.
View SRTS analyst ratings or view top-rated stocks.

2 brokerages have issued 1-year price targets for Sensus Healthcare's stock. Their SRTS share price forecasts range from $13.00 to $14.00. On average, they expect the company's stock price to reach $13.50 in the next twelve months. This suggests a possible upside of 14.5% from the stock's current price.
View analysts price targets for SRTS or view top-rated stocks among Wall Street analysts.

Sensus Healthcare's stock was trading at $7.22 on January 1st, 2022. Since then, SRTS stock has increased by 63.3% and is now trading at $11.79.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our SRTS earnings forecast.

Sensus Healthcare, Inc. (NASDAQ:SRTS) issued its quarterly earnings data on Thursday, August, 4th. The company reported $0.21 EPS for the quarter, topping analysts' consensus estimates of $0.18 by $0.03. The company earned $12.08 million during the quarter, compared to analyst estimates of $10.28 million. Sensus Healthcare had a net margin of 61.26% and a trailing twelve-month return on equity of 41.49%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Sensus Healthcare investors own include Ring Energy (REI), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Nabriva Therapeutics (NBRV), Sangamo Therapeutics (SGMO), Viking Therapeutics (VKTX), Vaxart (VXRT), Amarin (AMRN), Palatin Technologies (PTN) and QUALCOMM (QCOM).

(SRTS) raised $20 million in an initial public offering on Wednesday, March 30th 2016. The company issued 1,800,000 shares at $10.00-$12.00 per share. Joseph Gunnar and Feltl and Company served as the underwriters for the IPO and Neidiger, Tucker, Bruner was co-manager.

Sensus Healthcare trades on the NASDAQ under the ticker symbol "SRTS."

Sensus Healthcare's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.28%), Millennium Management LLC (1.25%), Navellier & Associates Inc. (0.72%), Empirical Financial Services LLC d.b.a. Empirical Wealth Management (0.58%), UBS Group AG (0.58%) and Bailard Inc. (0.21%). Insiders that own company stock include Javier Rampolla, Joseph C Sardano, Michael Sardano, Nicolas Soro, Samuel O'rear, Stephen Brad Cohen and William H Mccall.
View institutional ownership trends.

Shares of SRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SRTS stock can currently be purchased for approximately $11.79.

Sensus Healthcare (NASDAQ:SRTS) has a market capitalization of $195.20 million and generates $27.04 million in revenue each year. The company earns $4.12 million in net income (profit) each year or $1.51 on an earnings per share basis.

Sensus Healthcare's mailing address is 851 BROKEN SOUND PARKWAY NW SUITE 215, BOCA RATON FL, 33487. The official website for the company is www.sensushealthcare.com. The company can be reached via phone at (561) 922-5808, via email at kgolodetz@lhai.com, or via fax at 561-948-2071.